Diagnosis and Staging of Head and Neck Cancer, Step by Step
What happens between the first abnormal sign and a treatment plan: biopsy, endoscopy, imaging, HPV/EBV biomarkers, TNM staging and the tumour board.
Diagnosis requires a tissue biopsy interpreted by a head and neck pathologist, combined with endoscopic examination and contrast CT or MRI. HPV (p16) and EBV testing refine the likely site of origin, PET-CT and chest imaging assess spread, and a multidisciplinary tumour board assigns the stage and recommends treatment.
Step 1: examination and tissue diagnosis
A biopsy — not a scan — establishes the diagnosis.
- Complete head and neck examination including the oral cavity, scalp, ears, neck, cranial nerves and flexible nasopharyngolaryngoscopy.
- Incisional biopsy of a visible mucosal lesion; fine-needle aspiration or core biopsy of a neck node. Avoid open excisional node biopsy as the first step.
- Pathology reports should name the histological type, grade, depth of invasion (oral cavity), margins where applicable, perineural and lymphovascular invasion, and p16/HPV or EBER/EBV status when relevant.
Step 2: imaging and biomarkers
Imaging defines how far the tumour extends; biomarkers can reveal where it started.
NCCN work-up for head and neck cancers includes a complete head and neck examination, biopsy, CT with contrast and/or MRI, PET-CT and chest CT where indicated, and dental evaluation with extractions of teeth with a poor prognosis within the radiation field before radiotherapy begins.
| Test | What it answers |
|---|---|
| Contrast CT neck / chest | Bone involvement, nodal necrosis, chest metastases, airway assessment |
| Contrast MRI | Soft-tissue and skull-base extension, perineural spread, tongue-base and nasopharyngeal detail |
| FDG PET-CT | Occult primary, distant metastasis, treatment response in selected cases |
| p16 IHC ± HPV DNA/RNA ISH | Whether an oropharyngeal cancer is HPV-driven; determines AJCC 8 stage group |
| Plasma EBV DNA / EBER | Nasopharyngeal carcinoma risk stratification and recurrence monitoring |
| Dental panoramic radiograph | Dental clearance before radiotherapy; reduces osteoradionecrosis risk |
Step 3: TNM staging and the tumour board
Stage is assigned only after pathology, imaging and biomarkers are combined.
TNM describes the primary tumour (T), regional lymph nodes (N) and distant metastasis (M). Important modern refinements include separate AJCC 8 stage groups for HPV-mediated (p16-positive) oropharyngeal cancer, depth of invasion in oral cavity cancer, and distinct systems for nasopharyngeal, thyroid and salivary gland cancers. A small tonsil cancer with several neck nodes can be stage I in the HPV-positive system — which is why the p16 result is essential.
A multidisciplinary tumour board should agree the stage and the intent of treatment (curative, organ-preserving, palliative) before the first treatment is delivered. This is the single best moment to ask about functional outcomes, clinical trials and second opinions.
Ask for a written, English-language summary of stage, histology, biomarker results and the proposed plan. International patients need this document both for a second opinion and for continuation of care at home.
Six questions to ask before treatment starts
- What is the exact diagnosis, subsite and stage, and which staging system was used?
- Is the tumour HPV/p16-positive or EBV-associated, and was the test confirmed?
- Is the intent curative, organ-preserving or palliative, and what is the alternative?
- Which modality comes first, and why — surgery, radiotherapy, chemoradiotherapy or systemic therapy?
- What functional changes (speech, swallowing, breathing, appearance) should I expect?
- Is a clinical trial available, and will I receive the full pathology, imaging and dose records in English?
Frequently asked questions
Can a scan diagnose cancer without a biopsy?
No. Imaging can strongly suggest cancer and define its extent, but treatment decisions require tissue. Exceptions are rare and protocol-defined (for example some thyroid nodules diagnosed by cytology). Insist on a pathology report before starting radiotherapy or chemotherapy.
What is the difference between clinical and pathological stage?
Clinical stage (cTNM) is based on examination and imaging before treatment. Pathological stage (pTNM) adds the surgical specimen findings — margins, depth of invasion, number of nodes and extranodal extension. Pathological findings often determine whether adjuvant radiotherapy or chemoradiotherapy is needed.
Why is dental clearance required before radiotherapy?
Radiation reduces salivary flow and bone vascularity, raising the lifetime risk of dental decay and osteoradionecrosis of the jaw. Teeth with a poor prognosis inside the radiation field are extracted beforehand with time to heal, and a fluoride and oral-care programme is started.
Should I get a second opinion on my biopsy?
For rare histologies, salivary gland tumours, sarcoma, melanoma, or an unexpected p16/HPV result, yes. Request the original slides or a block and ask for review by a dedicated head and neck pathologist; discordance can change the entire treatment plan.
Sources for this guide
Applying this to your own case?
Start with a remote review of your records, then compare the written plan with the options you have at home.
Records checklist How to compare plansMedical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.